The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…
WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered a service agreement with Sino Biopharm, an innovative R&D-driven pharmaceutical group in China, to develop a first-in-class monoclonal antibody (mAb) targeting an undisclosed area. Under this…
ICON plc a leading global healthcare intelligence and clinical research organization, has received multiple prestigious awards in the second half of 2024, further solidifying its position as a top performer in the clinical research industry. For the second consecutive year,…
Colorectal Cancer Breakthrough: Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC Bristol Myers Squibb has announced that the Colorectal Cancer European Commission (EC) has approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) as the…
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s cutting-edge tNova platform to accelerate drug discovery and deliver innovative…
Grifols, a global healthcare leader and prominent manufacturer of plasma-derived medicines, has achieved the distinction of being ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices (DJSI). This marks the company’s fifth consecutive year in the…
UCB has announced results from the ORCHESTRA proof-of-concept study evaluating minzasolmin, an investigational oral small molecule developed in collaboration with Novartis to inhibit alpha-synuclein misfolding in early-stage Parkinson’s disease. Unfortunately, the study did not meet its primary and secondary clinical…
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics, a biotech company specializing in the discovery and development of innovative oral peptide therapies. This acquisition includes Nimble’s lead investigational oral peptide IL23R inhibitor, currently in preclinical development for psoriasis…
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional approval of WELIREG® (belzutifan), an oral hypoxia-inducible factor-2…
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast…
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not induce anti-drug antibodies (ADAs) after repeat administrations at therapeutic doses,…
Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the San Antonio Breast Cancer Symposium 2024 (SABCS). ADELA is a…